Separation and purification method of pneumocandin B0 serine analog

Abstract

The invention relates to a separation and purification method of a pneumocandin B0 serine analog. The separation and purification method comprises the following steps of (a) performing chromatographyenrichment for the first time through polymer substrate chromatogram fillings, performing isocratic elution, and collecting parts of which the purity is greater than 30%; (b) performing chromatographyenrichment for the second time through chromatogram fillings having hydrophilic effects, performing isocratic elution, and collecting parts of which the purity is greater than 60%; (c) performing chromatography enrichment for the third time through antiphase silica gel substrate chromatogram fillings, performing isocratic elution, and collecting parts of which the purity is greater than 80%; and(d) after purifying for the third time, performing decompressed concentration on chromatography liquid of which the pneumocandin B0 serine analog purity is greater than 80%, removing a solvent, and performing freeze-drying so as to obtain the pneumocandin B0 serine analog. Through the adoption of the preparation method disclosed by the invention, the pneumocandin B0 serine analog of which the purity is greater than 80% is subjected to structure identification, and a base is established for further performing biological activity screening or performing biological activity screening after structure modification.

Description

technical field

[0001] The invention belongs to the field of biopharmaceuticals, and relates to a method for separating and purifying pneumocidine B0 serine analogues, in particular to a method for separating and purifying pneumocidine B0 serine analogues from pneumocidine B0 crude products containing serine analogues method. Background technique

[0002] Fungi are conditional pathogens for healthy humans and are harmless to the human body under normal circumstances; however, when the body's resistance decreases, it may cause local or systemic fungal infections. In recent years, due to the clinical abuse of cytotoxic drugs, immunosuppressants, broad-spectrum antibiotics and hormonal drugs, not only the immunity of the patient's body has been suppressed, but also the micro-ecological balance in the body has been destroyed, making the originally non-pathogenic fungi dominant bacteria, thereby inducing fungal infection; coupled with the development of open treatment methods su...

Images